Replimune Group (NASDAQ:REPL) Hits New 12-Month High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) hit a new 52-week high on Monday . The company traded as high as $12.97 and last traded at $12.54, with a volume of 41626 shares trading hands. The stock had previously closed at $12.44.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REPL. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Tuesday. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and an average price target of $16.80.

Replimune Group Trading Down 2.5 %

The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The firm’s 50-day simple moving average is $11.42 and its 200 day simple moving average is $9.49.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of REPL. Nisa Investment Advisors LLC raised its holdings in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new stake in Replimune Group during the 2nd quarter worth about $57,000. Arizona State Retirement System acquired a new stake in Replimune Group during the 2nd quarter worth about $108,000. Quest Partners LLC raised its holdings in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Replimune Group during the 1st quarter valued at about $140,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.